NASDAQ:ALXNAlexion Pharmaceuticals Stock Price, Forecast & News

$116.28

-2.64 (-2.22 %)

(As of 06/2/2020 04:00 PM ET)

Add

Compare

Today's Range

$114.42

Now: $116.28▼

$118.31

50-Day Range

$96.23

MA: $104.09▼

$119.90

52-Week Range

$72.67

Now: $116.28▼

$134.84

Volume2.04 million shs

Average Volume2.41 million shs

Market Capitalization$25.68 billion

P/E Ratio10.95

Dividend YieldN/A

Beta1.43

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis; and partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Alexion Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 16 buy ratings, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $143.95, Alexion Pharmaceuticals has a potential upside of 23.8% from its current price of $116.28.
Amount of Analyst Coverage
Alexion Pharmaceuticals has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.1 Community Rank

Outperform Votes
Alexion Pharmaceuticals has received 1,231 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Alexion Pharmaceuticals has received 739 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Alexion Pharmaceuticals has received 62.49% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote “Outperform” if you believe ALXN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Alexion Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Alexion Pharmaceuticals does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alexion Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,431,103.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.03% of the stock of Alexion Pharmaceuticals is held by insiders.
Percentage Held by Institutions
88.97% of the stock of Alexion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1 Earnings and Valuation

Earnings Growth
Earnings for Alexion Pharmaceuticals are expected to grow by 3.82% in the coming year, from $9.94 to $10.32 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alexion Pharmaceuticals is 10.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 15.73.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alexion Pharmaceuticals is 10.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.56.
Price to Earnings Growth Ratio
Alexion Pharmaceuticals has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Alexion Pharmaceuticals has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.72 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:ALXN

Previous Symbol

CUSIP01535110

CIK899866

Webwww.alexion.com

Phone475-230-2596

Debt

Debt-to-Equity Ratio0.21

Current Ratio4.35

Quick Ratio3.82

Price-To-Earnings

Trailing P/E Ratio10.95

Forward P/E Ratio11.70

P/E Growth0.94

Sales & Book Value

Annual Sales$4.99 billion

Price / Sales5.14

Cash Flow$11.42 per share

Price / Cash Flow10.18

Book Value$50.91 per share

Price / Book2.28

Profitability

EPS (Most Recent Fiscal Year)$9.74

Net Income$2.40 billion

Net Margins44.83%

Return on Equity21.96%

Return on Assets14.70%

Miscellaneous

Employees3,082

Outstanding Shares220,830,000

Market Cap$25.68 billion

Next Earnings Date7/22/2020 (Estimated)

OptionableOptionable

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

How has Alexion Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALXN shares have increased by 38.8% and is now trading at $116.28. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alexion Pharmaceuticals?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings, 16 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alexion Pharmaceuticals.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Alexion Pharmaceuticals.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported $3.22 EPS for the quarter, topping the consensus estimate of $2.71 by $0.51. The biopharmaceutical company earned $1.44 billion during the quarter, compared to analysts' expectations of $1.36 billion. Alexion Pharmaceuticals had a net margin of 44.83% and a return on equity of 21.96%. The company's revenue was up 26.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.39 earnings per share. View Alexion Pharmaceuticals' earnings history.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY20 earnings guidance on Wednesday, May, 6th. The company provided earnings per share guidance of $10.45-$10.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.96. The company issued revenue guidance of $5.23-$5.33 billion, compared to the consensus revenue estimate of $5.51 billion.

What price target have analysts set for ALXN?

24 equities research analysts have issued 12-month target prices for Alexion Pharmaceuticals' shares. Their forecasts range from $110.00 to $180.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $143.95 in the next year. This suggests a possible upside of 23.8% from the stock's current price. View analysts' price targets for Alexion Pharmaceuticals.

Has Alexion Pharmaceuticals been receiving favorable news coverage?

News articles about ALXN stock have been trending positive recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alexion Pharmaceuticals earned a news impact score of 2.6 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAlexion Pharmaceuticals.

Are investors shorting Alexion Pharmaceuticals?

Alexion Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 4,840,000 shares, an increase of 6.6% from the April 30th total of 4,540,000 shares. Based on an average daily trading volume, of 2,740,000 shares, the days-to-cover ratio is presently 1.8 days. Approximately 2.2% of the shares of the company are sold short. View Alexion Pharmaceuticals' Current Options Chain.

Who are some of Alexion Pharmaceuticals' key competitors?

Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Alibaba Group (BABA), Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Micron Technology (MU), Celgene (CELG), AbbVie (ABBV), Walt Disney (DIS), Visa (V) and Biogen (BIIB).

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the following people:

Dr. Ludwig N. Hantson, CEO & Director (Age 56)
Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)
Ms. Anne-Marie Law, Exec. VP and Chief Patient & Employee Experience Officer (Age 52)
Mr. Brian M. Goff, Exec. VP & Chief Commercial Officer (Age 50)
Dr. John J. Orloff, Exec. VP and Head of R&D (Age 62)

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.43%), State Street Corp (5.02%), Clearbridge Investments LLC (2.97%), Swedbank (1.56%), Geode Capital Management LLC (1.48%) and AQR Capital Management LLC (1.24%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini, John J Orloff, Ludwig Hantson and Paul J Clancy. View institutional ownership trends for Alexion Pharmaceuticals.

Which major investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Nomura Holdings Inc., Morgan Stanley, Morgan Stanley, Invesco Ltd., Baird Financial Group Inc., Calamos Advisors LLC, and State of Michigan Retirement System. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, and Indrani Lall Franchini. View insider buying and selling activity for Alexion Pharmaceuticals.

Which major investors are buying Alexion Pharmaceuticals stock?

ALXN stock was bought by a variety of institutional investors in the last quarter, including Camber Capital Management LP, DNB Asset Management AS, TimesSquare Capital Management LLC, BlackRock Inc., Scharf Investments LLC, Orbimed Advisors LLC, AQR Capital Management LLC, and 1832 Asset Management L.P.. View insider buying and selling activity for Alexion Pharmaceuticals.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $116.28.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $25.68 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. Alexion Pharmaceuticals employs 3,082 workers across the globe.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is www.alexion.com.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff